Page 33 - Read Online

Page 328 Kapaki et al. Neuroimmunol Neuroinflammation 2020;7:319-29 I http://dx.doi.org/10.20517/2347-8659.2019.26

REFERENCES
1. McKhann G, Drachman D, Folsn M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-
ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology
1984;34:939-44.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s
disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement 2011;7:270-79.
3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. Toward defining the preclinical stages of Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s Assocation workgroups on diagnostic guidelines for Alzheimer’s
disease. Alzheimers Dement 2011;7:280-92.
4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. The diagnosis of dementia due to Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s
disease. Alzheimer’s Dement 2011;7:263-69.
5. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the
IWG-2 criteria. Lancet Neurol 2014;13:614-29.
6. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE):
consensus working group report. Brain 2019;142:1503-27.
7. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. NIA-AA Research Framework: Toward a biological definition of
Alzheimer’s disease. Alzheimers Dement 2018;14:535-62.
8. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H. Recommendations to standardize preanalytical confounding
factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012;6:419-30.
9. Paraskevas GP, Kaselimis D, Kourtidou E, Constantinides V, Bougea A, et al. Cerebrospinal fluid biomarkers as a diagnostic tool of the
underlying pathology of primary progressive aphasia. J Alzheimers Dis 2017;55:1453-61.
10. Bourbouli M, Kapaki E, Petropoulou O, Paraskevas GP. Improved performance of CSF dementia biomarker measurements over time: the
effect of quality control and harmonization programs. Biomark Applic 2018; doi: 10.29011/BMAP-126.100026.
11. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer’s disease diagnosis: discrimination
from normal ageing and other dementias in the Greek population. Eur J Neurol 2003;10:119-28.
12. Folstein M, Folstein S, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J
Psychiatr Res 1975;12:189-98.
13. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000;55:1621-26.
14. Jack CR Jr. PART and SNAP. Acta Neuropathol 2014;128:773-6.
15. Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, et al. Recommendations for CSF AD biomarkers in the diagnostic
evaluation of dementia. Alzheimer’s Dement 2017;13:274-84.
16. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid b 42/40 CSF concentration ratio in the diagnostics of Alzheimer’s
Disease: validation of two novel assays. J Alzheimer’s Dis 2015;43:183-91.
17. Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease fluid biomarkers. J Alzheimers Dis 2018;62:1125-40.
18. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, et al Sensitivity of revised diagnostic criteria for the behavioural variant
of frontotemporal dementia. Brain 2011;134:2456-77.
19. Lleó A, Irwin DJ, Illán-Gala I, McMillan CT, Wolk DA, et al. A 2-Step cerebrospinal algorithm for the selection of frontotemporal lobar
degeneration subtypes. JAMA Neurol 2018;75:738-45.
20. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, et al. Alzheimer’s disease-subcortical vascular disease spectrum in a
hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab 2016;36:95-113.
21. Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E, et al. CSF biomarker profile and diagnostic value in vascular
dementia. Eur J Neurol 2009;16:205-11.
22. Paraskevas GP, Constantinides VC, Pyrgelis ES, Kapaki E. Mixed Small Vessel Disease in a Patient with Dementia with Lewy Bodies.
Brain Sci 2019;9. pii: E159
23. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron 2013;80:1347-58.
24. Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, et al. Neuropathological background of phenotypical variability in
frontotemporal dementia. Acta Neuropathol 2011;122:137-53.
25. Dong Y, Chen Y. The role of ubiquitinated TDP-43 in amyotrophic lateral sclerosis. Neuroimmunol Neuroinflammation 2018;5:5.
26. McCleery J, Flicker L, Richard E, Quinn TJ. When is Alzheimer’s not dementia-Cochrane commentary on the national institute on ageing
and Alzheimer’s association research framework for Alzheimer’s disease. Age Ageing 2019;48:174-7.
27. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, et al. Diagnosis and management of dementia with Lewy bodies: fourth
consensus report of the DLB Consortium. Neurology 2017;89:88-100.
28. Skogseth R, Hortobágyi T, Soennesyn H, Chwiszczuk L, Ffytche D, et al. Accuracy of clinical diagnosis of dementia with lewy bodies
versus neuropathology. J Alzheimer’s Dis 2017;59:1139-52.
29. Paraskevas GP, Bougea A, Constantinides VC, Bourbouli M, Petropoulou O, et al. In vivo prevalence of alzheimer biomarkers in
dementia with lewy bodies. Dement Geriatr Cogn Disord 2019;47:289-96.
30. Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, et al. CSF biomarkers profile in CADASIL-a model of pure vascular dementia:
usefulness in differential diagnosis in the dementia disorder. Int J Alzheimers Dis. 2010;2010:959257.